CoChat

Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision

Open access

The DOI matches its Crossref record; 184 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.

Abstract

Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.

Overview

CoChat Summary

TL;DR

This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.

Key findings

  • Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
  • Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
  • Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
  • Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.

Methods

  • Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
  • The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
  • Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.

Limitations

  • The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
  • It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
  • It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/jof3040057

Cites

184 of 184 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 A map showing completed country estimates of fungal diseases by August 2017.
Figure 1 A map showing completed country estimates of fungal diseases by August 2017.CC BY · PubMed Central
Figure 2 Prevalence of invasive aspergillosis in a continental level. * p < 0.05.
Figure 2 Prevalence of invasive aspergillosis in a continental level. * p < 0.05.CC BY · PubMed Central
Figure 3 CPA prevalence across continents. * p < 0.05.
Figure 3 CPA prevalence across continents. * p < 0.05.CC BY · PubMed Central
Figure 4 ABPA prevalence across countries. ** p < 0.01.
Figure 4 ABPA prevalence across countries. ** p < 0.01.CC BY · PubMed Central
Figure 5 SAFS prevalence across continents. *** p < 0.001.
Figure 5 SAFS prevalence across continents. *** p < 0.001.CC BY · PubMed Central

Verification

Claims the paper makes

33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations

52 more claims · 6 with their cited sources checked

Create a free account to see all 186 claims and to verify the 39 references still open.

See all claims — free account
  • Probably not a substantial claim. 80
  • It may state two separate claims as one. 82
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 184 references

Research works printed but not linked: 6

  1. Denning, 2013, Global fungal Burden, Mycoses, 56, 13
  2. The Fungal Infection Trust (2011, January 18). How common are fungal diseases?. Proceedings of the Fungal Research Trust 20th Anniversary Meeting, London, UK. Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf.
  3. Jayasekera, 2013, The burden of serious fungal infections in Sri Lanka, Mycoses, 56, 103
  4. Gugnani, 2017, Burden of serious fungal infections in Bangladesh, Eur. J. Clin. Microbiol. Infect. Dis., 36, 965, 10.1007/s10096-017-2921-z · DOI · Paper page
  5. Samayoa, B., Isern, V., Serra, L., Rivera, B.E., Nikiforov, M., Arathoon, E., Samayoa, C., Vallès, X., Prieto, L., and Álvarez, C. (2010, January 18–23). Preliminary results of a prospective cohort of HIV+ patients in Guatemala. Proceedings of the XVIII International AIDS Conference, Vienna, Austria.
  6. Gopinathan, 2002, The Epidemiological Features and Laboratory Results of Fungal Keratitis, Eye, 21, 555

Cited by

Items 901–1,000 of 2,932

Metadata

Authors
Bongomin, F., Gago, S., Oladele, R., & Denning, D.
Affiliations
University of Manchester (GB)
Corresponding author
Denning, David
Venue
Journal of Fungi
Publisher
MDPI AG
Published
2017-10-18
Volume
3
Issue
4
Pages
57
ISSN
2309-608X (ISSN-L)
OpenAlex
W2767031614
Cited by
2,953
References
192
Citations by year
2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
FWCI
22.27
Type
journal article
Language
en
Open access
Locations
  • Journal of Fungi (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
Keywords
fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.